Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TK2 | O00142 | 3/20 | 0.42 |
| ▸ | TK1 | P04183 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10479252 | 0.84 | LMNA (0.44) | — | |
| SCHEMBL6719212 | 0.84 | GRIA1 (0.43) | — | |
| SCHEMBL2641394 | 0.83 | MAPK1 (0.51) | TYMPMAPK1HPGDTK2TK1 | |
| SCHEMBL16382269 | 0.83 | MAPK1 (0.51) | TYMPMAPK1HPGDTK2TK1 | |
| SCHEMBL7834551 | 0.82 | EGFR (0.43) | — | |
| SCHEMBL4088248 | 0.81 | UPP1 (0.57) | TYMPMAPK1HPGD | |
| SCHEMBL6029548 | 0.81 | TYMP (0.50) | TYMPMAPK1HPGDALDH1A1NPSR1 | |
| SCHEMBL8444953 | 0.81 | TYMP (0.50) | TYMPMAPK1HPGDALDH1A1NPSR1 | |
| SCHEMBL6029061 | 0.81 | HPGD (0.53) | TYMPMAPK1HPGDTK2TK1 | |
| SCHEMBL7215304 | 0.81 | TYMP (0.50) | TYMPMAPK1HPGDTK2TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136587-A1 | N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS | D. E. SHAW RESEARCH, LLC | 2025-05-01 | — | — | US | disclosed |
| EP-4472627-A2 | N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS | D.E. Shaw Research, LLC (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-118922185-A | N3-substituted uracil compounds as TRPA1 inhibitors | D·E·萧尔研究有限责任公司 | 2024-11-08 | — | — | CN | disclosed |
| WO-2023150592-A2 | N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS | D.E. SHAW RESEARCH, LLC (US) | 2023-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136587-A1 | N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS | TRPA1, TRPV1, SLC28A1 | TYMP 276/4885MAPK1 1876/4885HPGD 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.